These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 26216910)

  • 1. Human lymphocytic B-leukemia cell line treatment with the bacterial toxin listeriolysin O and rituximab (anti-CD20 antibody): Effects of similar localization of their receptors.
    Gryzik M; Grzywocz Z; Wasilewska D; Kawiak J; Stachowiak R; Bielecki J; Hoser G
    Int J Immunopathol Pharmacol; 2015 Sep; 28(3):329-40. PubMed ID: 26216910
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rituximab infusion promotes rapid complement depletion and acute CD20 loss in chronic lymphocytic leukemia.
    Kennedy AD; Beum PV; Solga MD; DiLillo DJ; Lindorfer MA; Hess CE; Densmore JJ; Williams ME; Taylor RP
    J Immunol; 2004 Mar; 172(5):3280-8. PubMed ID: 14978136
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: role of cytokines, complement, and caspases.
    Chow KU; Sommerlad WD; Boehrer S; Schneider B; Seipelt G; Rummel MJ; Hoelzer D; Mitrou PS; Weidmann E
    Haematologica; 2002 Jan; 87(1):33-43. PubMed ID: 11801463
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytotoxicity of purified listeriolysin O on mouse and human leukocytes and leukaemia cells.
    Stachowiak R; Łyżniak M; Grabowska M; Roeske K; Jagielski T; Bielecki J; Budziszewska BK; Hoser G; Kawiak J
    BMC Biotechnol; 2014 Aug; 14():77. PubMed ID: 25134983
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Monitoring of the Complement System Status in Patients With B-Cell Malignancies Treated With Rituximab.
    Felberg A; Taszner M; Urban A; Majeranowski A; Jaskuła K; Jurkiewicz A; Stasiłojć G; Blom AM; Zaucha JM; Okrój M
    Front Immunol; 2020; 11():584509. PubMed ID: 33329558
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mutations resulting in the formation of hyperactive complement convertases support cytocidal effect of anti-CD20 immunotherapeutics.
    Felberg A; Urban A; Borowska A; Stasiłojć G; Taszner M; Hellmann A; Blom AM; Okrój M
    Cancer Immunol Immunother; 2019 Apr; 68(4):587-598. PubMed ID: 30725204
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The chimeric anti-CD20 antibody rituximab induces apoptosis in B-cell chronic lymphocytic leukemia cells through a p38 mitogen activated protein-kinase-dependent mechanism.
    Pedersen IM; Buhl AM; Klausen P; Geisler CH; Jurlander J
    Blood; 2002 Feb; 99(4):1314-9. PubMed ID: 11830481
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rituximab and alemtuzumab induce a nonclassic, caspase-independent apoptotic pathway in B-lymphoid cell lines and in chronic lymphocytic leukemia cells.
    Stanglmaier M; Reis S; Hallek M
    Ann Hematol; 2004 Oct; 83(10):634-45. PubMed ID: 15309525
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Killing of CLL and NHL cells by rituximab and ofatumumab under limited availability of complement.
    Okroj M; Eriksson I; Österborg A; Blom AM
    Med Oncol; 2013 Dec; 30(4):759. PubMed ID: 24198205
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synergism between fludarabine and rituximab revealed in a follicular lymphoma cell line resistant to the cytotoxic activity of either drug alone.
    Di Gaetano N; Xiao Y; Erba E; Bassan R; Rambaldi A; Golay J; Introna M
    Br J Haematol; 2001 Sep; 114(4):800-9. PubMed ID: 11564066
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Specific targeting of a pore-forming toxin (listeriolysin O) to LHRH-positive cancer cells using LHRH targeting peptide.
    Kheirandish MH; Jaliani HZ; Rahmani B; Nikukar H
    Toxicon; 2019 Jun; 164():82-86. PubMed ID: 30991063
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanism of action of type II, glycoengineered, anti-CD20 monoclonal antibody GA101 in B-chronic lymphocytic leukemia whole blood assays in comparison with rituximab and alemtuzumab.
    Bologna L; Gotti E; Manganini M; Rambaldi A; Intermesoli T; Introna M; Golay J
    J Immunol; 2011 Mar; 186(6):3762-9. PubMed ID: 21296976
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Listeriolysin O immunogenetic adjuvant enhanced potency of hepatitis C virus NS3 DNA vaccine.
    Pouriayevali MH; Bamdad T; Sadat SM; Sadeghi SA; Sabahi F; Mahdavi M; Aghasadeghi MR
    IUBMB Life; 2019 Oct; 71(10):1645-1652. PubMed ID: 31298809
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Level of CD 20-expression and efficacy of rituximab treatment in patients with resistant or relapsing B-cell prolymphocytic leukemia and B-cell chronic lymphocytic leukemia.
    Perz J; Topaly J; Fruehauf S; Hensel M; Ho AD
    Leuk Lymphoma; 2002 Jan; 43(1):149-51. PubMed ID: 11908720
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sensitivity of B-cell chronic lymphocytic leukemia to Rituximab and Campath-1H and correlation with the expression of cell cycle regulatory proteins.
    Grdisa M
    Croat Med J; 2004 Apr; 45(2):136-41. PubMed ID: 15103748
    [TBL] [Abstract][Full Text] [Related]  

  • 16. T cells armed with anti-CD3 x anti-CD20 bispecific antibody enhance killing of CD20+ malignant B cells and bypass complement-mediated rituximab resistance in vitro.
    Gall JM; Davol PA; Grabert RC; Deaver M; Lum LG
    Exp Hematol; 2005 Apr; 33(4):452-9. PubMed ID: 15781336
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytotoxic effects of the trifunctional bispecific antibody FBTA05 in ex-vivo cells of chronic lymphocytic leukaemia depend on immune-mediated mechanism.
    Boehrer S; Schroeder P; Mueller T; Atz J; Chow KU
    Anticancer Drugs; 2011 Jul; 22(6):519-30. PubMed ID: 21637160
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antilymphoma effects of anti-HLA-DR and CD20 monoclonal antibodies (Lym-1 and Rituximab) on human lymphoma cells.
    Liu C; DeNardo G; Tobin E; DeNardo S
    Cancer Biother Radiopharm; 2004 Oct; 19(5):545-61. PubMed ID: 15650447
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Membrane microdomain sphingolipids are required for anti-CD20-induced death of chronic lymphocytic leukemia B cells.
    Hammadi M; Youinou P; Tempescul A; Tobón G; Berthou C; Bordron A; Pers JO
    Haematologica; 2012 Feb; 97(2):288-96. PubMed ID: 22058197
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transient down-modulation of CD20 by rituximab in patients with chronic lymphocytic leukemia.
    Jilani I; O'Brien S; Manshuri T; Thomas DA; Thomazy VA; Imam M; Naeem S; Verstovsek S; Kantarjian H; Giles F; Keating M; Albitar M
    Blood; 2003 Nov; 102(10):3514-20. PubMed ID: 12893761
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.